Quanterix Expanding Transformative Biomarker Technology Portfolio Into Oncology
Launching Test Bed for up to 10-plex assays with Simoa Sensitivity
and Specificity to
“The SP-X and accompanying large planar array menu of multiplex panels
represent the latest evolution of the industry-leading Simoa technology
and marks our continued commitment to driving today’s healthcare
revolution into oncology,” said
With the same unprecedented sensitivity and precision of current Simoa systems, the SP-X™ offers exceptional multiplexing biomarker detection capabilities in a compact size. For the first time, researchers are able to access over one thousand assay configurations for oncology up to 10-plex without sacrificing sensitivity on an easy-to-use, incredibly robust instrument. The assay broad menu covers more than 50 analytes and offers researchers the ability to easily develop custom homebrew assays, further extending the range of applications to include PK/PD and immunogenicity assays. The chemiluminescent SP-X™ platform was designed to transform oncology and immuno-oncology research, where the ability to measure multiple analytes simultaneously is critical but has not been possible with sufficient sensitivity until now. With the SP-X™, researchers in these areas will be able to more quickly see the effects of certain drugs on individual cancer patients even at the earliest stages of the disease.
“Cancer is one of the leading causes of death, with more than 1.7 million new cases expected to be diagnosed in the U.S. alone this year. Creating safe and effective drugs to combat the disease has posed challenges for drug developers, and this new platform represents the product of a major investment on our part to address an important unmet need in oncology research,” continued Hrusovsky.
The SP-X™ also offers state-of-the-art imaging and data analysis, complete with proprietary acquisition and machine learning algorithms, and streamlined semi-automated sample preparation workflows. The compact benchtop instrument comes complete with an intuitive touch-screen interface and onboard high-resolution camera, requiring minimal maintenance and calibration.
The new SP-X™ will be on display today for the first time at the
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as "may," "will," "expect," "plan," "anticipate," "estimate,"
"intend" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements in this
news release are based on Quanterix’ expectations and assumptions as of
the date of this press release. Each of these forward-looking statements
involves risks and uncertainties. Factors that may cause Quanterix’
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed
in Quanterix’ filings with the
Lindsay Poole, 617-502-4300